Business Wire

First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology

Share

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and the Vall d’Hebron Institute of Oncology (VHIO), one of Europe’s leading cancer research organizations, today announced that the first blood-based cancer testing services in Europe based on Guardant Health’s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing facility in Barcelona.

Guardant Health and VHIO established the partnership in January 2021 to give more patients access to Guardant Health’s industry leading liquid biopsy technology. This testing service will provide essential genomic information through comprehensive genomic profiling (CGP) for patients with any solid cancerous tumor. From a simple blood draw, the test identifies patients with actionable biomarkers more quickly than starting with tissue biopsy. The VHIO testing services will be available for clinical research and clinical care.

“The opening of this service will give more patients with advanced cancer access to blood-based biomarker testing and help their healthcare professionals make more informed treatment decisions,” said Helmy Eltoukhy, Guardant Health co-CEO. “We look forward to continuing to build our partnership with VHIO, working together to ensure cancer patients across Spain and beyond have access to the latest innovations in precision oncology and striving to achieve better patient outcomes.”

“The incorporation of this technology in VHIO will enable us to continue advancing towards precision medicine, improving the use of liquid biopsy to detect genomic alterations in tumors and come out with more effective treatments for patients,” said Dr Josep Tabernero, Director of VHIO and Head of the Medical Oncology Department of Vall d’Hebron University Hospital. “Our goal is to ensure that the use of liquid biopsy becomes a common diagnostic option, so that oncologists can use it to determine the best treatment for their patients. Thanks to this agreement, we can move towards this scenario.”

“Implementing this technology in our lab is a leap forward in the liquid field for us. We have performed an in-house extensive analytical validation of the assay and we attain very high levels of sensitivity and specificity with the test,” said Dr Ana Vivancos, Group Leader of the VHIO Cancer Genomics Group, where this testing will take place. “Guardant Health’s next generation broad panel sequencing technology gives us the capabilities to screen for a large number of gene mutations and provides complete genomic results without the need for a tissue sample.”

In 2020, there were over 282,000 new cancer cases in Spain and approximately 113,000 cancer deaths, with lung cancer and colon cancer being the leading causes of cancer-related death.1 Guardant Health’s tests are used by oncologists around the world to guide treatment decisions across solid tumor cancers, and by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening.

About Vall d’Hebron Institute of Oncology

Established in 2006, the Vall d’Hebron Institute of Oncology (VHIO) is a leading comprehensive cancer research center of excellence where its scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. Undertaking one of Spain’s most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of our patients. VHIO is one of the seven leading European cancer research centers that have joined forces to create Cancer Core Europe, a Cancer Association carrying out innovative research propelling cancer medicine into a new era through translational research.

Guardant Health Forward-Looking Statement

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

References

  1. International Agency for Research on Cancer. World Health Organization. https://gco.iarc.fr/today/data/factsheets/populations/724-spain-fact-sheets.pdf. Accessed online May 18, 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Guardant Health Contacts

Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417

Media Contact:
Michele Rest
press@guardanthealth.com
+1 215-910-2138

Vall d’Hebron Institute of Oncology Contact

Media Contact:
Bianca Pont
bpont@vhio.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rubix Receives $100 Million Investment from LDA Capital5.7.2022 23:36:00 EEST | Press release

Rubix Blockchain Pte Ltd (Rubix) announced today it has secured a $100 million investment from LDA Capital Ltd to grow global operations, support the transition to Web3, and expand its green blockchain community. “Rubix is a gamechanger for international transactions. It’s exactly the type of innovative disruptor we look to partner with,” said Warren P. Baker III, managing partner at LDA Capital. “What sets the Rubix blockchain apart is its environmentally friendly crypto framework and focus on leveraging the Web3 technology to address some of the biggest issues society faces today. This isn’t just a coin, it’s a true transformation in how online transactions are processed.” This investment will allow Rubix to optimize growth in the Web3 space, expanding education opportunities, policy development, and Web2 to Web3 transition – enabling partners to build various apps on the platform including those that address social and environmental issues. The funds will also be used to increase in

Laserfiche Named a Leader in Nucleus Research Content Services and Collaboration Value Matrix 20225.7.2022 19:22:00 EEST | Press release

Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has been named a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for its deep industry expertise, ease of use and process automation features. Out of the 15 vendors evaluated, Laserfiche ranked highest for both functionality and usability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005673/en/ MPI CIO Joel Manfredo (left) shares upcoming plans to deploy Laserfiche as an enterprise solution with Laserfiche CIO Thomas Phelps. (Photo: Business Wire) “Over the past three years, digitization has become a core component of business survival across organizational sizes and industry types,” the report states. “Now, the ongoing prevalence of fully remote and hybrid work structures has highlighted the importance of having modern solutions for content management and collaborat

Clever Cloud Selects French Kalray for Its High-performance Storage Solutions to Optimize Its New Data Center5.7.2022 19:00:00 EEST | Press release

Clever Cloud, a European provider of automation and optimization solutions for websites and applications hosting, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider of a new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, announce a partnership aimed at strengthening the relationship between the two companies for the deployment of next-generation storage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005197/en/ Clever Cloud Clever Cloud, which is currently setting up in a third Parisian data center and strengthening its technical platform, has chosen to partner with French company Kalray and its Flashbox™, a new generation of NVMe storage array that can accommodate up to 24 PCI Express (NVMe) SSDs, for its high-performance storage solution. PERFORMANCE, RESILIENCE AND OPENNESS Without a host CPU (Central Processing Unit),

AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism5.7.2022 18:00:00 EEST | Press release

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating that ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury (AKI) has been published in the journal, Frontiers in Medicine-Nephrology. The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI. The publication is available now online at https://www.frontiersin.org/articles/10.3389/fmed.2022.931293/abstract. This study provides further insight into the mechanism of action of ilofotase alfa, showing that adenosine receptor signaling plays a role in the activity of the drug by restoring homeostasis through conversion of extracellular ATP into adenosine activating anti-inflammatory adenosine receptor signaling in common AKI animal models. The 1000 U/Kg dose tested in this study is, comparable to the dose currently being te

Innovaderm is Pleased to Announce the Acquisition of Excelsus Statistics5.7.2022 16:30:00 EEST | Press release

Innovaderm, a leading CRO in dermatology, has expanded its biometrics capacity following the acquisition of Excelsus Statistics, a Montreal-based company specialized in biostatistical and SAS programming services with a special expertise in adaptive trial design, as well as activities in many different therapeutic areas. “We are pleased to grow our Biometrics team with the addition of new talent,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm has a reputation for excellence in clinical research in dermatology, as well as attracting committed professionals in the field. Our collective expertise will allow us to offer biometrics services across different therapeutic areas and fulfill the growing needs of our clients.” Since 2014, Excelsus Statistics has served as a collaborator in many studies managed by Innovaderm. The integration of the two companies will allow Excelsus Statistics’ existing clients to now have access to full CRO services including data manageme

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom